Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fimasartan + amlodipine + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Fimasartan + amlodipine + rosuvastatin** is an oral fixed-dose combination of three small molecules marketed by Boryung as **Dukaro** for patients who require both antihypertensive therapy with fimasartan/amlodipine and lipid lowering with rosuvastatin. Fimasartan selectively antagonizes the angiotensin II type 1 receptor, amlodipine inhibits calcium influx through L-type calcium channels, and rosuvastatin competitively inhibits HMG-CoA reductase. The combination addresses essential hypertension and dyslipidemia in a single film-coated tablet; Boryung lists 30/5/5 mg, 30/5/10 mg, 60/5/5 mg, and 60/5/10 mg strength combinations. A randomized Phase III study evaluated the triple regimen in patients with essential hypertension and dyslipidemia inadequately controlled with fimasartan monotherapy. ([pharm.boryung.co.kr](https://pharm.boryung.co.kr/product/search_detail.do?SEQ=307))
- Brand names
- Dukaro
- Other names
- fimasartan/amlodipine/rosuvastatin
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on fimasartan + amlodipine + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fimasartan + amlodipine + rosuvastatin.